These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16565253)

  • 1. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality.
    Schmitt CP; Odenwald T; Ritz E
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S78-80. PubMed ID: 16565253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasculotropic effects of calcimimetics.
    Koleganova N; Piecha G; Ritz E
    Curr Opin Nephrol Hypertens; 2010 Jan; 19(1):32-6. PubMed ID: 19816173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease.
    Torres PA; De Broe M
    Kidney Int; 2012 Jul; 82(1):19-25. PubMed ID: 22437409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium-sensing receptor as a potential modulator of vascular calcification in chronic kidney disease.
    Caudrillier A; Mentaverri R; Brazier M; Kamel S; Massy ZA
    J Nephrol; 2010; 23(1):17-22. PubMed ID: 20091482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
    Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Fahrleitner-Pammer A; Kienreich K; Horina JH; Drechsler C; März W; Ofner M; Pieber TR; Pilz S
    Cardiovasc Res; 2012 Apr; 94(1):10-9. PubMed ID: 22334595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular effects of VDR and CaSR activation].
    Brancaccio D; Cozzolino M
    G Ital Nefrol; 2009; 26 Suppl 49():S18-22. PubMed ID: 19941274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of calcimimetics in children with normal kidney function.
    VanSickle JS; Srivastava T; Alon US
    Pediatr Nephrol; 2019 Mar; 34(3):413-422. PubMed ID: 29552709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical effects of calcimimetics in hyperparathyroidism.
    Peacock M
    J Musculoskelet Neuronal Interact; 2004 Dec; 4(4):414-5. PubMed ID: 15758287
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of calcium-sensing receptor in mineral ion metabolism and inherited disorders of calcium-sensing.
    Chattopadhyay N; Brown EM
    Mol Genet Metab; 2006 Nov; 89(3):189-202. PubMed ID: 16919492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcimimetics--fooling the calcium receptor.
    Ritz E
    Pediatr Nephrol; 2005 Jan; 20(1):15-8. PubMed ID: 15517414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way.
    Tastan I; Schreckenberg R; Mufti S; Abdallah Y; Piper HM; Schlüter KD
    Cardiovasc Res; 2009 Apr; 82(1):77-83. PubMed ID: 19168854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum aldosterone is correlated positively to parathyroid hormone (PTH) levels in patients with primary hyperparathyroidism.
    Brunaud L; Germain A; Zarnegar R; Rancier M; Alrasheedi S; Caillard C; Ayav A; Weryha G; Mirallie E; Bresler L
    Surgery; 2009 Dec; 146(6):1035-41. PubMed ID: 19958930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is PTH a risk factor for cardiovascular calcifications in haemodialysis?
    Cozzolino M; Brancaccio D
    Nephrol Dial Transplant; 2008 Mar; 23(3):1067-8; author reply 1068-9. PubMed ID: 18045828
    [No Abstract]   [Full Text] [Related]  

  • 17. [Basic and clinical aspects of calcimimetics. Calcimimetic is indicated for patients with surgically uncontrollable hyperparathyroidism].
    Tominaga Y
    Clin Calcium; 2008 Jan; 18(1):67-71. PubMed ID: 18175874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The calcium-sensing receptor and calcimimetics in blood pressure modulation.
    Smajilovic S; Yano S; Jabbari R; Tfelt-Hansen J
    Br J Pharmacol; 2011 Oct; 164(3):884-93. PubMed ID: 21410453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol.
    Carrillo-López N; Alvarez-Hernández D; González-Suárez I; Román-García P; Valdivielso JM; Fernández-Martín JL; Cannata-Andía JB
    Nephrol Dial Transplant; 2008 Nov; 23(11):3479-84. PubMed ID: 18556746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Basic and clinical aspects of calcimimetics. Treatment of secondary hyperparathyroidism in dialysis patients with calcimimetics].
    Tanaka M; Fukagawa M
    Clin Calcium; 2008 Jan; 18(1):89-93. PubMed ID: 18175877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.